
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Ehrlichiosis medical therapy
Introduction
Overview
Overview
The mainstay of therapy in ehrlichiosis is antimicrobial therapy. Doxycycline is the drug of choice to treat ehrlichiosis.
Medical Therapy
Medical Therapy
Doxycycline is the first line treatment for adults and children of all ages and should be initiated immediately whenever ehrlichiosis is suspected.
Antimicrobial regimen
- 1. Human Monocytic Ehrlichiosis or Human Granulocytic Anaplasmosis (adult) [1] [2]
- Preferred regimen: Doxycycline 100 mg PO/IV q12h for 7-14 days
- Note: Patients should be treated for at least 3 days after the fever subsides and until there is evidence of clinical improvement
- Alternative regimen (1): Chloramphenicol 500mg PO qid
- Alternative regimen (2): Rifampin 600 mg PO/IV qd for 7-10 days
- 2. Human Monocytic Ehrlichiosis or Human Granulocytic Anaplasmosis (pediatric)
- 2.1 β₯ 8 years old
- Preferred regimen: Doxycycline 2 mg/kg IV/PO q12h (Maximum, 200 mg/day) for 10 days
- 2.2 < 8 years old without Lyme disease
- Preferred regimen: Doxycycline 2 mg/kg IV/PO q12h (Maximum, 200 mg/day) for 4-5 days (or 3 days after resolution of fever)
- 2.3 co-infected with Lyme disease
- Preferred regimen: Doxycycline, then Amoxicillin 50 mg/kg in 3 divided doses (Maximum, 500 mg/dose) OR Cefuroxime 30 mg/kg in 2 divided doses (Maximum, 500 mg/dose) for 14 days
References
References
- β “Ehrlichiosis CDC centers for the disease control and prevention”. Invalid parameter “centers” in
<ref>tag. The supported parameters are: dir, follow, group, name. - β Bartlett, John (2012). Johns Hopkins ABX guideΒ : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBNΒ 978-1449625580.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
